On October 9, 2025 Amplia Therapeutics Limited (ASX: ATX), referred to as "Amplia" or "the Company", reported an update from the ongoing ACCENT clinical trial, which is investigating the company’s leading FAK inhibitor, narmafotinib, in combination with the chemotherapies gemcitabine and Abraxane for the treatment of advanced pancreatic cancer. The trial is being conducted across sites in Australia and Korea (Press release, Amplia Therapeutics, OCT 9, 2025, View Source [SID1234656519]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
LATEST TRIAL DATA AND KEY FINDINGS
An additional confirmed partial response and an unconfirmed partial response have been recorded as part of the data analysis from the ACCENT Trial following the data cut off on 25 Sept 2025. These new findings bring the Objective Response Rate (ORR) to 33%, a notable improvement over the 23% response rate previously observed with chemotherapy alone1. The objective response rate measures only the partial and complete responses that have been confirmed by an additional scan after 2 months. When all confirmed and unconfirmed responses are taken together, the response rate is 42%.
The mean duration on trial—a key indicator of the drug combination’s ability to halt cancer progression— is 219 days, which is substantially longer than the duration typically achieved with chemotherapy alone. Notably, seven patients have remained on the study for at least 12 months, and two patients have continued for more than 18 months. These results are consistent with previously reported data2 showing a median Progression Free Survival (mPFS) of 7.6 months, representing a two-month improvement compared to chemotherapy alone. There are currently nine (9) patients on study.